Companies will jointly market their complementary products, the Bio-Rad Variant II Turbo HST testing system and the Sysmex HST-N haematology automation line, as a complete integrated testing solution
Bio-Rad Laboratories has announced a co-marketing agreement with Sysmex America, a medical diagnostic instrument manufacturer and information systems developer.
The two companies will jointly market their complementary products, the Bio-Rad Variant II Turbo HST testing system and the Sysmex HST-N haematology automation line, as a complete, integrated testing solution.
This combination of Bio-Rad's market-leading assay for hemoglobin A1C and Sysmex's automated testing platform will enable laboratories to provide superior diabetes monitoring services to doctors and their patients throughout the United States.
"We are very pleased to work with Sysmex to offer clinical laboratories an enhanced solution for haemoglobin testing".
"The combination of these two product lines will provide many benefits to laboratories including automated sample processing, the elimination of sample splitting, and an easy way to dramatically improve operating efficiency while reducing costs and errors".
"Customer feedback has been very positive and we look forward to introducing this new solution soon," said John Goetz, Bio-Rad's vice president of clinical diagnostics.
"We are delighted to continue our long standing history with Bio-Rad Laboratories".
"The Variant II Turbo HST haemoglobin testing system is a perfect compliment to the hematology automation line that Sysmex currently offers," said John Kershaw, president, Sysmex America.
"With the addition of A1C to our automation line, we can truly manage all the testing of the lavender top haematology sample tubes in the laboratory."
